[{"id":"3174eb09-547d-4053-9bb7-a8326b4fcbac","acronym":"","url":"https://clinicaltrials.gov/study/NCT03841617","created_at":"2021-07-05T17:20:24.574Z","updated_at":"2025-02-25T12:27:07.917Z","phase":"Phase 2","brief_title":"The Use of 124-I-PET/CT Whole Body and Lesional Dosimetry in Differentiated Thyroid Cancer","source_id_and_acronym":"NCT03841617","lead_sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","biomarkers":" BRAF • TG","pipe":" | ","alterations":" BRAF mutation","tags":["BRAF • TG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 07/29/2019","start_date":" 07/29/2019","primary_txt":" Primary completion: 02/01/2030","primary_completion_date":" 02/01/2030","study_txt":" Completion: 02/01/2030","study_completion_date":" 02/01/2030","last_update_posted":"2025-02-24"},{"id":"58d26922-dd62-4243-8588-89fbcbf5d940","acronym":"","url":"https://clinicaltrials.gov/study/NCT02152995","created_at":"2021-03-24T14:59:26.184Z","updated_at":"2025-02-25T12:26:08.615Z","phase":"Phase 2","brief_title":"Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer","source_id_and_acronym":"NCT02152995","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • KRAS • BRAF • NRAS • HRAS • EGF","pipe":" | ","alterations":" KRAS mutation • NRAS mutation • BRAF V600 • BRAF wild-type • RAS wild-type • HRAS mutation • KRAS G12 • NRAS Q61 • KRAS G13 • NRAS G12 • NRAS G13 • KRAS Q61","tags":["HER-2 • KRAS • BRAF • NRAS • HRAS • EGF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • NRAS mutation • BRAF V600 • BRAF wild-type • RAS wild-type • HRAS mutation • KRAS G12 • NRAS Q61 • KRAS G13 • NRAS G12 • NRAS G13 • KRAS Q61"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • omipalisib (GSK2126458)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 34","initiation":"Initiation: 08/14/2014","start_date":" 08/14/2014","primary_txt":" Primary completion: 08/25/2021","primary_completion_date":" 08/25/2021","study_txt":" Completion: 01/25/2026","study_completion_date":" 01/25/2026","last_update_posted":"2025-02-24"},{"id":"de85007a-8a96-4d92-b410-2aebe8f02c18","acronym":"","url":"https://clinicaltrials.gov/study/NCT06007924","created_at":"2023-08-23T15:11:08.435Z","updated_at":"2025-02-25T15:13:43.406Z","phase":"Phase 2","brief_title":"A Study of Avutometinib and Defactinib in People With Thyroid Cancer","source_id_and_acronym":"NCT06007924","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" BRAF • ALK • RET • NF1 • NTRK","pipe":" | ","alterations":" BRAF V600E • ALK rearrangement • BRAF V600K • RAS mutation • RET mutation • RET rearrangement","tags":["BRAF • ALK • RET • NF1 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • ALK rearrangement • BRAF V600K • RAS mutation • RET mutation • RET rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avmapki (avutometinib) • Fakzynja (defactinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 08/16/2023","start_date":" 08/16/2023","primary_txt":" Primary completion: 08/16/2027","primary_completion_date":" 08/16/2027","study_txt":" Completion: 08/16/2027","study_completion_date":" 08/16/2027","last_update_posted":"2025-02-13"},{"id":"897d9629-7c12-4d49-92b0-10b4a3de5a1f","acronym":"","url":"https://clinicaltrials.gov/study/NCT02973997","created_at":"2025-02-26T08:59:58.704Z","updated_at":"2025-02-26T08:59:58.704Z","phase":"Phase 2","brief_title":"Lenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC)","source_id_and_acronym":"NCT02973997","lead_sponsor":"Academic and Community Cancer Research United","biomarkers":" CD8 • PD-L2","pipe":"","alterations":" ","tags":["CD8 • PD-L2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Lenvima (lenvatinib)"],"overall_status":"Completed","enrollment":" Enrollment 57","initiation":"Initiation: 02/07/2018","start_date":" 02/07/2018","primary_txt":" Primary completion: 08/15/2022","primary_completion_date":" 08/15/2022","study_txt":" Completion: 10/08/2023","study_completion_date":" 10/08/2023","last_update_posted":"2024-07-01"},{"id":"ad64e5d0-95d3-4f41-a430-f89469610dd7","acronym":"","url":"https://clinicaltrials.gov/study/NCT03914300","created_at":"2023-12-06T21:16:15.541Z","updated_at":"2024-07-02T16:34:26.125Z","phase":"Phase 2","brief_title":"Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer","source_id_and_acronym":"NCT03914300","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1 • PD-1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1 • PD-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule) • ABP 206 (nivolumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 27","initiation":"Initiation: 02/10/2020","start_date":" 02/10/2020","primary_txt":" Primary completion: 10/31/2024","primary_completion_date":" 10/31/2024","study_txt":" Completion: 10/31/2024","study_completion_date":" 10/31/2024","last_update_posted":"2024-06-14"},{"id":"2504abd7-8283-416b-9334-520a0e4d328c","acronym":"CROWN","url":"https://clinicaltrials.gov/study/NCT05309655","created_at":"2022-04-04T13:52:41.797Z","updated_at":"2024-07-02T16:34:36.955Z","phase":"Phase 1","brief_title":"Cardiac Outcomes With Near-Complete Estrogen Deprivation","source_id_and_acronym":"NCT05309655 - CROWN","lead_sponsor":"Wake Forest University Health Sciences","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" HR positive • HER-2 negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative"],"overall_status":"Recruiting","enrollment":" Enrollment 90","initiation":"Initiation: 09/02/2022","start_date":" 09/02/2022","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2027","study_completion_date":" 12/01/2027","last_update_posted":"2024-06-10"},{"id":"7ee65b79-49ff-449c-ae18-0e2f8ded36d4","acronym":"","url":"https://clinicaltrials.gov/study/NCT06440850","created_at":"2024-06-08T04:18:06.782Z","updated_at":"2024-07-02T16:34:59.043Z","phase":"Phase 2","brief_title":"Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation","source_id_and_acronym":"NCT06440850","lead_sponsor":"City of Hope Medical Center","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zelboraf (vemurafenib) • Cotellic (cobimetinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 21","initiation":"Initiation: 11/30/2024","start_date":" 11/30/2024","primary_txt":" Primary completion: 11/30/2026","primary_completion_date":" 11/30/2026","study_txt":" Completion: 11/30/2026","study_completion_date":" 11/30/2026","last_update_posted":"2024-06-04"},{"id":"b6b2754e-5306-4023-a3e5-75d3f7fe5848","acronym":"","url":"https://clinicaltrials.gov/study/NCT05620134","created_at":"2022-11-17T14:57:00.380Z","updated_at":"2024-07-02T16:35:08.649Z","phase":"Phase 1/2","brief_title":"Study of JK08 in Patients With Unresectable Locally Advanced or Metastatic Cancer","source_id_and_acronym":"NCT05620134","lead_sponsor":"Salubris Biotherapeutics Inc","biomarkers":" HER-2 • BRAF","pipe":" | ","alterations":" BRAF mutation • BRAF V600","tags":["HER-2 • BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • SAL008"],"overall_status":"Recruiting","enrollment":" Enrollment 263","initiation":"Initiation: 10/17/2022","start_date":" 10/17/2022","primary_txt":" Primary completion: 10/17/2025","primary_completion_date":" 10/17/2025","study_txt":" Completion: 02/20/2026","study_completion_date":" 02/20/2026","last_update_posted":"2024-04-19"},{"id":"77303f62-6e39-4d65-a62b-36ab4c8e233e","acronym":"","url":"https://clinicaltrials.gov/study/NCT04266249","created_at":"2021-01-18T20:43:47.844Z","updated_at":"2025-02-25T13:53:10.003Z","phase":"Phase 2","brief_title":"CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy","source_id_and_acronym":"NCT04266249","lead_sponsor":"ECOG-ACRIN Cancer Research Group","biomarkers":" ER • PGR","pipe":" | ","alterations":" HER-2 positive • HER-2 negative","tags":["ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • docetaxel • Perjeta (pertuzumab) • Kadcyla (ado-trastuzumab emtansine) • albumin-bound paclitaxel • Herzuma (trastuzumab-pkrb) • Ontruzant (trastuzumab-dttb) • Ogivri (trastuzumab-dkst) • Trazimera (trastuzumab-qyyp) • Herwenda (trastuzumab biosimilar)"],"overall_status":"Recruiting","enrollment":" Enrollment 2156","initiation":"Initiation: 03/13/2020","start_date":" 03/13/2020","primary_txt":" Primary completion: 10/31/2026","primary_completion_date":" 10/31/2026","study_txt":" Completion: 12/31/2038","study_completion_date":" 12/31/2038","last_update_posted":"2024-04-18"},{"id":"cb8d2781-175e-47d3-a3e8-c2f88771d5b3","acronym":"","url":"https://clinicaltrials.gov/study/NCT00381641","created_at":"2023-11-22T18:15:18.641Z","updated_at":"2024-07-02T16:35:11.050Z","phase":"Phase 2","brief_title":"Sunitinib Malate in Treating Patients With Thyroid Cancer That Did Not Respond to Iodine I 131 and Cannot Be Removed by Surgery","source_id_and_acronym":"NCT00381641","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" RET","pipe":"","alterations":" ","tags":["RET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sunitinib"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 63","initiation":"Initiation: 08/08/2006","start_date":" 08/08/2006","primary_txt":" Primary completion: 12/31/2016","primary_completion_date":" 12/31/2016","study_txt":" Completion: 03/08/2025","study_completion_date":" 03/08/2025","last_update_posted":"2024-04-08"},{"id":"8fc7055a-dde1-4071-9f3b-d016eed452de","acronym":"","url":"https://clinicaltrials.gov/study/NCT04891198","created_at":"2021-05-18T12:02:07.091Z","updated_at":"2024-07-02T16:35:11.517Z","phase":"Phase 2","brief_title":"ENVAFOLIMAB Single-agent Treatment in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT04891198","lead_sponsor":"3D Medicines (Sichuan) Co., Ltd.","biomarkers":" TMB","pipe":" | ","alterations":" TMB-H","tags":["TMB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TMB-H"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Enweida (envafolimab)"],"overall_status":"Recruiting","enrollment":" Enrollment 126","initiation":"Initiation: 08/06/2021","start_date":" 08/06/2021","primary_txt":" Primary completion: 08/30/2027","primary_completion_date":" 08/30/2027","study_txt":" Completion: 04/30/2028","study_completion_date":" 04/30/2028","last_update_posted":"2024-04-03"},{"id":"5c9414e8-7220-42f4-8441-a2cd65e87bf3","acronym":"","url":"https://clinicaltrials.gov/study/NCT05463107","created_at":"2022-07-18T14:01:53.359Z","updated_at":"2024-07-02T16:35:14.098Z","phase":"","brief_title":"Correlation Between Various Urinary Exosomal Protein Biomarkers and Pathological Manifestation in Thyroid Follicular Neoplasm: Early and Pre-operative Diagnosis of Follicular Thyroid Cancer","source_id_and_acronym":"NCT05463107","lead_sponsor":"National Taiwan University Hospital","biomarkers":" KRT19 • KRT8 • TG","pipe":"","alterations":" ","tags":["KRT19 • KRT8 • TG"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 08/01/2022","start_date":" 08/01/2022","primary_txt":" Primary completion: 07/31/2025","primary_completion_date":" 07/31/2025","study_txt":" Completion: 07/31/2028","study_completion_date":" 07/31/2028","last_update_posted":"2024-03-19"},{"id":"af734147-b4c2-4351-87af-14a4c5e4f2fa","acronym":"","url":"https://clinicaltrials.gov/study/NCT04462471","created_at":"2021-01-18T21:27:12.136Z","updated_at":"2024-07-02T16:35:17.410Z","phase":"Phase 1","brief_title":"Vemurafenib Plus Copanlisib in Radioiodine-Refractory (RAIR) Thyroid Cancers","source_id_and_acronym":"NCT04462471","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation • BRAF V600","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zelboraf (vemurafenib) • Aliqopa (copanlisib)"],"overall_status":"Completed","enrollment":" Enrollment 8","initiation":"Initiation: 06/26/2020","start_date":" 06/26/2020","primary_txt":" Primary completion: 09/29/2023","primary_completion_date":" 09/29/2023","study_txt":" Completion: 09/29/2023","study_completion_date":" 09/29/2023","last_update_posted":"2024-02-28"},{"id":"ae4bc21b-56da-43de-9d91-fda963c4eb35","acronym":"","url":"https://clinicaltrials.gov/study/NCT05541380","created_at":"2022-09-15T16:06:07.463Z","updated_at":"2024-07-02T16:35:28.349Z","phase":"","brief_title":"A Taiwanese Oncogenetic Panel and Integrated Clinical Data Registry Study for Advanced Thyroid Cancer Patients (TOPICS-THYROID)","source_id_and_acronym":"NCT05541380","lead_sponsor":"National Health Research Institutes, Taiwan","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"],"overall_status":"Recruiting","enrollment":" Enrollment 300","initiation":"Initiation: 08/29/2022","start_date":" 08/29/2022","primary_txt":" Primary completion: 12/31/2030","primary_completion_date":" 12/31/2030","study_txt":" Completion: 12/31/2030","study_completion_date":" 12/31/2030","last_update_posted":"2023-11-22"},{"id":"d6544d5c-22e0-428e-b270-2a60bc0e02bc","acronym":"","url":"https://clinicaltrials.gov/study/NCT04447183","created_at":"2021-01-18T21:23:59.877Z","updated_at":"2024-07-02T16:35:32.204Z","phase":"Phase 2","brief_title":"The Safety and Effectiveness of rhTSH in Radioiodine Treatment for Patients With Differentiated Thyroid Cancer.","source_id_and_acronym":"NCT04447183","lead_sponsor":"Suzhou Zelgen Biopharmaceuticals Co.,Ltd","biomarkers":" TG","pipe":"","alterations":" ","tags":["TG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e recombinant human thyroid stimulating hormone for injection (rhTSH)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 11/23/2020","start_date":" 11/23/2020","primary_txt":" Primary completion: 08/01/2024","primary_completion_date":" 08/01/2024","study_txt":" Completion: 10/01/2024","study_completion_date":" 10/01/2024","last_update_posted":"2023-10-23"},{"id":"3dcb1660-e495-40f3-9888-b807678bb239","acronym":"","url":"https://clinicaltrials.gov/study/NCT05442060","created_at":"2022-07-01T20:56:49.222Z","updated_at":"2024-07-02T16:35:40.793Z","phase":"Phase 2","brief_title":"To Evaluate OBI-833/OBI-821 in Combination With First-Line Erlotinib in Patients With EGFR-Mutated, Globo H-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT05442060","lead_sponsor":"OBI Pharma, Inc","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e erlotinib • OBI-833"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 07/27/2022","start_date":" 07/27/2022","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 05/31/2026","study_completion_date":" 05/31/2026","last_update_posted":"2023-08-07"},{"id":"e366ce2b-98fa-4136-b5ca-4e02accd6dd7","acronym":"","url":"https://clinicaltrials.gov/study/NCT02432274","created_at":"2021-01-18T11:38:24.007Z","updated_at":"2025-02-25T16:14:40.249Z","phase":"Phase 1/2","brief_title":"Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies and Young Adults With Osteosarcoma","source_id_and_acronym":"NCT02432274","lead_sponsor":"Eisai Limited","biomarkers":" FGF21","pipe":"","alterations":" ","tags":["FGF21"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lenvima (lenvatinib) • ifosfamide • etoposide IV"],"overall_status":"Completed","enrollment":" Enrollment 117","initiation":"Initiation: 12/29/2014","start_date":" 12/29/2014","primary_txt":" Primary completion: 07/18/2019","primary_completion_date":" 07/18/2019","study_txt":" Completion: 07/20/2022","study_completion_date":" 07/20/2022","last_update_posted":"2023-07-11"},{"id":"53537bf3-eae7-42ad-947c-fe82b3ec3eae","acronym":"ERRITI","url":"https://clinicaltrials.gov/study/NCT04619316","created_at":"2021-01-19T20:34:09.715Z","updated_at":"2024-07-02T16:35:45.180Z","phase":"Phase 2","brief_title":"Enhancing Radioiodine Incorporation Into Radio Iodine Refractory Thyroid Cancers With MAPK Inhibition","source_id_and_acronym":"NCT04619316 - ERRITI","lead_sponsor":"University Hospital, Essen","biomarkers":" TG","pipe":" | ","alterations":" BRAF mutation • BRAF wild-type","tags":["TG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • Tafinlar (dabrafenib)"],"overall_status":"Recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 02/05/2018","start_date":" 02/05/2018","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2023-06-22"},{"id":"730c77ad-1d00-4230-9649-63e238415e20","acronym":"MOLTHY","url":"https://clinicaltrials.gov/study/NCT04970134","created_at":"2021-07-21T13:52:40.805Z","updated_at":"2024-07-02T16:35:50.005Z","phase":"","brief_title":"Spanish Study for Molecular Characterization of Thyroid Carcinoma","source_id_and_acronym":"NCT04970134 - MOLTHY","lead_sponsor":"Grupo Español de Tratamiento de Tumores de Cabeza y Cuello","biomarkers":" PD-L1 • PD-1","pipe":"","alterations":" ","tags":["PD-L1 • PD-1"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 150","initiation":"Initiation: 06/14/2021","start_date":" 06/14/2021","primary_txt":" Primary completion: 01/25/2023","primary_completion_date":" 01/25/2023","study_txt":" Completion: 03/01/2024","study_completion_date":" 03/01/2024","last_update_posted":"2023-04-20"},{"id":"522b2880-fdc3-457c-bd7e-d2a0eb1974f6","acronym":"","url":"https://clinicaltrials.gov/study/NCT05668962","created_at":"2022-12-30T14:58:34.811Z","updated_at":"2024-07-02T16:35:50.690Z","phase":"Phase 2","brief_title":"Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC","source_id_and_acronym":"NCT05668962","lead_sponsor":"Massachusetts General Hospital","biomarkers":" RET • TG","pipe":" | ","alterations":" RET fusion","tags":["RET • TG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RET fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Retevmo (selpercatinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 03/01/2023","start_date":" 03/01/2023","primary_txt":" Primary completion: 03/01/2024","primary_completion_date":" 03/01/2024","study_txt":" Completion: 01/01/2025","study_completion_date":" 01/01/2025","last_update_posted":"2023-04-13"},{"id":"2e2eca56-d2c6-4ba6-84f4-22cb6d82234a","acronym":"","url":"https://clinicaltrials.gov/study/NCT02393690","created_at":"2021-01-18T11:24:58.815Z","updated_at":"2024-07-02T16:35:56.531Z","phase":"Phase 2","brief_title":"Iodine I-131 With or Without Selumetinib in Treating Patients With Recurrent or Metastatic Thyroid Cancer","source_id_and_acronym":"NCT02393690","lead_sponsor":"Academic and Community Cancer Research United","biomarkers":" TG","pipe":"","alterations":" ","tags":["TG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Koselugo (selumetinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 05/04/2015","start_date":" 05/04/2015","primary_txt":" Primary completion: 07/17/2020","primary_completion_date":" 07/17/2020","study_txt":" Completion: 12/31/2023","study_completion_date":" 12/31/2023","last_update_posted":"2023-02-02"},{"id":"4953a1bf-5abc-4d0f-a83c-e35443af9380","acronym":"","url":"https://clinicaltrials.gov/study/NCT04948437","created_at":"2021-07-02T12:52:35.475Z","updated_at":"2024-07-02T16:36:02.236Z","phase":"","brief_title":"Urinary Exosomal Biomarkers of Thyroglobulin and Galectin-3 for Prognosis and Follow-up in Patients of Thyroid Cancer","source_id_and_acronym":"NCT04948437","lead_sponsor":"National Taiwan University Hospital","biomarkers":" KRT19 • KRT8 • TG","pipe":"","alterations":" ","tags":["KRT19 • KRT8 • TG"],"overall_status":"Recruiting","enrollment":" Enrollment 103","initiation":"Initiation: 08/19/2021","start_date":" 08/19/2021","primary_txt":" Primary completion: 10/31/2024","primary_completion_date":" 10/31/2024","study_txt":" Completion: 10/31/2026","study_completion_date":" 10/31/2026","last_update_posted":"2022-10-18"},{"id":"1db27810-1326-4d7c-a744-d511488d5c3f","acronym":"","url":"https://clinicaltrials.gov/study/NCT05466812","created_at":"2022-07-20T12:56:24.373Z","updated_at":"2024-07-02T16:36:07.138Z","phase":"Phase 4","brief_title":"Efficacy of Sr-89 for Differentiated Thyroid Cancer With Bone Metastases","source_id_and_acronym":"NCT05466812","lead_sponsor":"Peking Union Medical College Hospital","biomarkers":" TG","pipe":"","alterations":" ","tags":["TG"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 07/13/2022","start_date":" 07/13/2022","primary_txt":" Primary completion: 07/13/2024","primary_completion_date":" 07/13/2024","study_txt":" Completion: 07/13/2025","study_completion_date":" 07/13/2025","last_update_posted":"2022-07-20"},{"id":"c0fb26e4-588f-4ea3-80da-f8b88b7324e9","acronym":"","url":"https://clinicaltrials.gov/study/NCT02702388","created_at":"2021-07-05T16:52:02.815Z","updated_at":"2025-02-25T16:04:25.407Z","phase":"Phase 2","brief_title":"A Trial of Lenvatinib (E7080) in Subjects With Iodine-131 Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 18 Milligram (mg) Daily Will Provide Comparable Efficacy to a 24 mg Starting Dose, But Have a Better Safety Profile","source_id_and_acronym":"NCT02702388","lead_sponsor":"Eisai Inc.","biomarkers":" FGF23 • TG","pipe":"","alterations":" ","tags":["FGF23 • TG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lenvima (lenvatinib)"],"overall_status":"Completed","enrollment":" Enrollment 241","initiation":"Initiation: 06/08/2017","start_date":" 06/08/2017","primary_txt":" Primary completion: 12/12/2019","primary_completion_date":" 12/12/2019","study_txt":" Completion: 09/10/2020","study_completion_date":" 09/10/2020","last_update_posted":"2021-11-24"}]